BuSpar Patent Listed By FDA Following Amended Declaration By Bristol
Executive Summary
FDA's listing of an additional patent on buspirone in the "Orange Book" reflects Bristol's amended declaration that the patent "covers the use of the approved product" BuSpar, FDA said in a Dec. 6 letter to the company.
You may also be interested in...
Generic Exclusivity "Incentive" Needs Review, FDA's Dickinson Says
The necessity of 180-day generic exclusivity should be reviewed, FDA Associate Counsel for Drugs Elizabeth Dickinson told the Food & Drug Law Institute conference on the Waxman/Hatch Act Dec. 11 in Washington, D.C.
Generic Exclusivity "Incentive" Needs Review, FDA's Dickinson Says
The necessity of 180-day generic exclusivity should be reviewed, FDA Associate Counsel for Drugs Elizabeth Dickinson told the Food & Drug Law Institute conference on the Waxman/Hatch Act Dec. 11 in Washington, D.C.
Bristol BuSpar Metabolite Data Requested By FDA Before Final Patent Listing
FDA is requesting additional information from Bristol-Myers Squibb on the company's BuSpar (buspirone) metabolite patent before permanently listing it in the "Orange Book."